Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Findings of phase III trials of the Bruton’s tyrosine kinase inhibitor evobrutinib in patients with relapsing multiple sclerosis were recently presented at the ACTRIMS Forum.
New data recently reported at the ACTRIMS Forum add to growing evidence of an aetiological role for Epstein–Barr virus infection in multiple sclerosis.
A new study has found evidence of α-synuclein aggregates — a key pathological hallmark of Parkinson disease — in the gut and brain in people and animals with inflammatory bowel disease.
T cells that are specific for B cells infected with Epstein–Barr virus are enriched in the cerebrospinal fluid of people with early multiple sclerosis, according to new research.
New research indicates that in a mouse model of Parkinson disease, α-synuclein is trafficked from the brain to the gut by CD11c-expressing macrophages.
Speaking at the XXVI World Congress of Neurology, Eva Feldman highlighted the global burden of diabetic peripheral neuropathy in people with type 2 diabetes and suggested dietary and lifestyle modifications that might help to reduce this burden.
Researchers in China and South Korea have developed a rapid immunodot assay to detect aquaporin 4-targeting IgG autoantibodies in the serum of individuals with neuromyelitis optica spectrum disorder.
Two new studies have provided important mechanistic insights into TDP-43 pathology, a hallmark of neurodegenerative conditions such as amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
A new study identifies LONRF2 as a protein quality control ubiquitin ligase that is induced in senescent neurons and seems to protect them against degeneration